Cantor Fitzgerald upgrades Supernus Pharmaceuticals stock rating on Qelbree sales outlook

Published 30/07/2025, 17:38
Cantor Fitzgerald upgrades Supernus Pharmaceuticals stock rating on Qelbree sales outlook

Investing.com - Cantor Fitzgerald upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from Neutral to Overweight on Wednesday, while raising its price target to $42.00 from $36.00. According to InvestingPro data, the company maintains a "GREAT" financial health score, with analyst targets ranging from $36 to $45.

The upgrade reflects Cantor Fitzgerald’s increased sales outlook for Qelbree, Supernus Pharmaceuticals’ non-stimulant medication for attention-deficit hyperactivity disorder (ADHD).

The research firm cited its "more positive outlook on Qelbree" as a key factor in the rating change, along with other minor adjustments across its income statement projections for the company.

Cantor Fitzgerald noted the new price target represents significant upside potential compared to Supernus Pharmaceuticals’ current trading price.

The $42.00 price target represents a $6.00 increase from the firm’s previous target of $36.00 for the biopharmaceutical company, which specializes in central nervous system disorders.

In other recent news, Supernus Pharmaceuticals reported its first-quarter 2025 earnings, revealing a net loss that missed analyst expectations. The company posted a GAAP net loss per share of $0.21, while analysts had anticipated earnings of $0.37 per share. However, Supernus’s revenue slightly exceeded forecasts, coming in at $149.8 million compared to the expected $146.9 million. In a significant development, Supernus is moving forward with its acquisition of Sage Therapeutics, having cleared a key regulatory hurdle with the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period.

The acquisition is valued at approximately $561 million in cash, with a potential increase to $795 million based on contingent value rights. Piper Sandler maintained its Neutral rating on Supernus, describing the acquisition as puzzling but acknowledging its potential to diversify the company. Cantor Fitzgerald also reiterated its Neutral rating, highlighting the acquisition’s provision of access to ZURZUVAE, an FDA-approved treatment for postpartum depression. These developments reflect Supernus’s strategic moves to expand its portfolio and address broader market opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.